BioMarin Pharmaceutical revenue and financials
$56.22Change from previous close: −2.29%Absolute change: −$1.32
In the fiscal year ended December 2025, BioMarin Pharmaceutical reported revenue of $3.22B (+12.87% year over year). Net income was $348.9M, a net margin of 10.8%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +12.87%
- 2025 vs 2024
- Net income growth
- −18.26%
- 2025 vs 2024
- Net margin
- 10.8%
- 2024: 15.0%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 828 | 573 | 159 | 176 | 305 | 85.4 | 48.3 | 20.2 | -8.8 | -228 |
| Depreciation and amortization | 79.6 | 96.4 | 104 | 102 | 108 | 105 | 105 | 95.7 | 87.9 | 96.9 |
| Capital expenditure | -103 | -85.4 | -96.7 | -121 | -95.6 | -114 | -145 | -145 | -199 | -148 |
| Investing cash flow | -414 | 136 | -111 | -20.0 | -366 | — | — | — | — | — |
| Financing cash flow | -42.4 | -526 | -18.7 | -18.7 | -0.0 | — | — | — | — | — |
| Share repurchases | -56.0 | -77.6 | -76.3 | 0.0 | 0.0 | -50.0 | 0.0 | 0.0 | — | — |
| Debt issued | — | — | — | 0.0 | 0.0 | — | — | — | — | — |
| Debt repaid | 0.0 | -495 | 0.0 | 0.0 | — | — | — | — | — | — |
| Effect of exchange rates | -2.5 | 4.8 | 1.3 | 0.0 | -0.1 | — | — | — | — | — |
| Net change in cash | 369 | 188 | 30.6 | 137 | -61.9 | — | — | — | — | — |
| Free cash flow | 725 | 487 | 62.6 | 54.9 | 209 | — | — | — | — | — |
| Levered free cash flow | 403 | 212 | -17.4 | 137 | 202 | — | — | — | — | — |